| Nov 20 |
Voyager selects gene therapy development candidate for Alzheimer’s disease
|
| Nov 20 |
Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease
|
| Nov 18 |
Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral
|
| Nov 14 |
Declining Stock and Decent Financials: Is The Market Wrong About Voyager Therapeutics, Inc. (NASDAQ:VYGR)?
|
| Nov 13 |
Q3 2024 Voyager Therapeutics Inc Earnings Call
|
| Nov 13 |
Voyager Therapeutics Inc (VYGR) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...
|
| Nov 13 |
Voyager Therapeutics, Inc. (VYGR) Q3 2024 Earnings Call Transcript
|
| Nov 12 |
Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 12 |
Voyager Therapeutics: Q3 Earnings Snapshot
|
| Nov 12 |
Voyager Therapeutics GAAP EPS of -$0.16 beats by $0.29, revenue of $24.63M beats by $12.93M
|
